Valuation: Agenus Inc.

Market Cap 28Cr 25Cr 24Cr 21Cr 40Cr 2.71TCr 41Cr 282.91Cr 112.01Cr 1.42TCr 106.95Cr 104.68Cr 4.47TCr P/E 2026 *
25.7x
P/E 2027 * -13.4x
Enterprise Value 28Cr 25Cr 24Cr 21Cr 40Cr 2.71TCr 41Cr 282.91Cr 112.01Cr 1.42TCr 106.95Cr 104.68Cr 4.47TCr EV / Sales 2026 *
2.28x
EV / Sales 2027 * 2.46x
Free-Float
93.73%
Yield 2026 *
-
Yield 2027 * -
1 day-2.76%
1 week+4.80%
Current month-36.25%
1 month-25.53%
3 months+5.85%
6 months+62.31%
Current year+101.59%
1 week 6.05
Extreme 6.05
6.58
1 month 6
Extreme 6
10.31
Current year 2.71
Extreme 2.71
10.31
1 year 2.71
Extreme 2.71
10.31
3 years 1.38
Extreme 1.38
19.69
5 years 1.38
Extreme 1.38
93.8
10 years 1.38
Extreme 1.38
135.8
Manager TitleAgeSince
Chief Executive Officer 73 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 73 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Director

1,179 0.0026%
01/10/26 Free

Director

4,443 0.0098%
10/08/26 Free

Chief Executive Officer

19,71,500 4.4054%
Change 5-day change 1-year change 3-year change Capi.($)
-2.76%+4.80%+52.90%-58.06% 28Cr
+2.41%+0.29%+39.41%+72.14% 6.47TCr
-0.15%+7.50%+11.42%+71.27% 5.48TCr
+0.57%+4.60%+7.71%+90.93% 5.35TCr
+0.37%+4.67%+26.68%+49.64% 4.6TCr
-1.21%+2.32%+21.50%+118.33% 4.29TCr
-0.37%+5.07%+243.23%+789.58% 4.01TCr
+0.05%+0.21%+18.06%+48.50% 3.35TCr
+1.19%-4.98%+26.31%-0.76% 2.4TCr
-0.38%+5.68%+38.39%+28.35% 2.37TCr
Average -0.03%+1.92%+48.56%+120.99% 3.83TCr
Weighted average by Cap. +0.39%+2.73%+46.02%+142.69%

Financials

2026 *2027 *
Net sales 13Cr 11Cr 10Cr 9.36Cr 18Cr 1.19TCr 18Cr 124.29Cr 49Cr 622.7Cr 47Cr 46Cr 1.96TCr 12Cr 10Cr 9.57Cr 8.67Cr 16Cr 1.1TCr 16Cr 115.12Cr 46Cr 576.78Cr 44Cr 43Cr 1.82TCr
Net income 3.94Cr 3.52Cr 3.25Cr 2.95Cr 5.51Cr 374.02Cr 5.6Cr 39Cr 15Cr 195.96Cr 15Cr 14Cr 617.82Cr -2.86Cr -2.55Cr -2.36Cr -2.13Cr -3.99Cr -271.02Cr -4.06Cr -28Cr -11Cr -142Cr -11Cr -10Cr -447.68Cr
Net Debt - -
Projected Income Statement - Annual - Agenus Inc.
Logo Agenus Inc.
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Employees
81
Date Price Change Volume
23/26/23 $6.330 -2.76% 5,10,514
22/26/22 $6.510 +1.72% 5,53,954
21/26/21 $6.400 -0.31% 7,89,683
20/26/20 $6.420 +3.88% 8,27,183
19/26/19 $6.180 +2.32% 7,34,955
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
MarketScreener Ratings - Agenus Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
6.330USD
Average target price
26.33USD
Spread / Average Target
+316.01%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Agenus Inc.
  1. Stock Market
  2. Stocks
  3. AGEN Stock